By Stephen Nakrosis
Shares of Allurion Technologies rallied after the company said patients lost weight and maintained muscle mass while using its Allurion Balloon and AI-Powered Virtual Care Suite.
The stock rose 42% to $3.36 in post-market trading on Tuesday, with 3 million shares changing hands. Shares touched a 52-week low of $2.15 on Monday, and have plummeted 96% in the past year.
Allurion said the data was included in four abstracts presented at the European Congress on Obesity, which showed that the company's products aided weight loss with and without the use of GLP-1s.
Data from one abstract indicated potential benefits from using the company's swallowable Procedureless intragastric balloon and Virtual Care Suite with normal dosing of GLP-1s, which built upon previous data.
GLP-1s used in combination with the Virtual Care Suite led to an average gain in lean body mass of 6.1%, the company said. Data was also presented showing that Allurion Balloon used in combination with GLP-1s leads to an average reduction in body weight of 21.2%.
The Allurion Program, which involved 2,000 patients treated between 2017 and 2024, showed an average 12.4% reduction in body weight after four months, and an average increase in muscle mass of 9.8% after six months.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
May 13, 2025 18:04 ET (22:04 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.